I
Immix Biopharma, Inc. (IMMX)
NCM – Real Time Price. Currency in USD
9.98
+0.26 (2.67%)
At close: Jun 26, 2026, 4:00 PM EDT
9.97
-0.01 (-0.10%)
After-hours: Jun 26, 2026, 5:38 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
9.98
+0.26 (2.67%)
At close: Jun 26, 2026, 4:00 PM EDT
9.97
-0.01 (-0.10%)
After-hours: Jun 26, 2026, 5:38 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $79.3M significantly exceed its total debt $1.0M, ensuring strong financial flexibility
Total current assets $92.3M exceed Total current liabilities $10.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$9.9M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.76 | 6.05 | 10 | |
| Quick ratio | 8.76 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 9.0 | |
| Debt to Assets | 0.01 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -2K | -5K | -115K | -365K | -436K |
| Operating Income | -8M | -16M | -23M | -27M | -36M |
| Net Income | -8M | -15M | -22M | -29M | -35M |
| EBITDA | -8M | -16M | -23M | -27M | -36M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 21.94 | 5.5 |
| Next quarter | N/A | 28.58 | 5.5 |
| Current year | N/A | 22.28 | 5.5 |
| Next year | N/A | -7.23 | 1.0 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 5.62 | 33.33 | 11.93 | 8.0 |
| Y/Y | 999 | -122.04 | -19.99 | -462.48 | 3.3 |
| 3y average | 999 | -54.57 | -16.73 | -49.53 | 3.3 |
| 5y average | 999 | -424.34 | -16.73 | -161.47 | 3.3 |
| Weighted average score | 4.5 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |